It was recently announced that the amount of antibodies provided by the BioNTech vaccine has decreased enough to not be enough to protect from COVID-19 after a certain period of time. However, as in Sinovac, there has been debate in BioNTech as to whether a third or even fourth dose should be taken. Today, the controversial third dose has been approved for use by the European Medicines Agency. The same decision was valid for the Moderna vaccine.
While the European Medicines Agency (EMA) mentioned that the third dose can be given to people with weakened immune systems for now, some important details about age were also given. According to the explanations, the time that children and adults should spend between the second and third dose will differ.
Those with weakened immunity will be able to take the 3rd dose
Marco Cavaleri, EMA’s Head of Biological Health Therapies and Vaccine Strategy, in his press release today, has concluded one of the most discussed issues in the field of pandemic for the last 1-2 weeks: the third dose in mRNA vaccines. In his statement, Cavaleri stated that EMA granted a third dose permission to BioNTech and Moderna. Those who experience a decrease in antibody levels and weakened immunity will also be able to receive the third dose of mRNA vaccines according to the decision.
Mentioning some details after the announcement of the permission, Cavaleri stated that children over the age of 12 can take this additional dose at least 28 days after the second dose. People between the ages of 18-55 will have to pass 6 months after the second dose before they can receive the third dose. Thus, the public’s health will continue to be protected until vaccines are updated, perhaps.
45313
